Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Loo, Vivian G.
Poirier, Louise
Miller, Mark A.
Oughton, Matthew
Libman, Michael D.
Michaud, Sophie
Bourgault, Anne-Marie
Nguyen, Tuyen
Frenette, Charles
Kelly, Mirabelle
Vibien, Anne
Brassard, Paul
Fenn, Susan
Dewar, Ken
Hudson, Thomas J.
Horn, Ruth
René, Pierre
Monczak, Yury
and
Dascal, André
2005.
A Predominantly Clonal Multi-Institutional Outbreak ofClostridium difficile–Associated Diarrhea with High Morbidity and Mortality.
New England Journal of Medicine,
Vol. 353,
Issue. 23,
p.
2442.
Bartlett, John G.
and
Perl, Trish M.
2005.
The NewClostridium difficile— What Does It Mean?.
New England Journal of Medicine,
Vol. 353,
Issue. 23,
p.
2503.
McDonald, L. Clifford
Killgore, George E.
Thompson, Angela
Owens, Robert C.
Kazakova, Sophia V.
Sambol, Susan P.
Johnson, Stuart
and
Gerding, Dale N.
2005.
An Epidemic, Toxin Gene–Variant Strain ofClostridium difficile.
New England Journal of Medicine,
Vol. 353,
Issue. 23,
p.
2433.
McDonald, L. Clifford
2005.
Clostridium difficile: Responding to a New Threat From an Old Enemy.
Infection Control & Hospital Epidemiology,
Vol. 26,
Issue. 8,
p.
672.
Pepin, J.
Saheb, N.
Coulombe, M.-A.
Alary, M.-E.
Corriveau, M.-P.
Authier, S.
Leblanc, M.
Rivard, G.
Bettez, M.
Primeau, V.
Nguyen, M.
Jacob, C.-E.
and
Lanthier, L.
2005.
Emergence of Fluoroquinolones as the Predominant Risk Factor for Clostridium difficile-Associated Diarrhea: A Cohort Study during an Epidemic in Quebec.
Clinical Infectious Diseases,
Vol. 41,
Issue. 9,
p.
1254.
Paterson, David L.
2006.
The Role of Antimicrobial Management Programs in Optimizing Antibiotic Prescribing within Hospitals.
Clinical Infectious Diseases,
Vol. 42,
Issue. Supplement_2,
p.
S90.
Stein, G. E.
and
Goldstein, E. J. C.
2006.
Fluoroquinolones and Anaerobes.
Clinical Infectious Diseases,
Vol. 42,
Issue. 11,
p.
1598.
Fordtran, John S.
2006.
Colitis Due toClostridium DifficileToxins: Underdiagnosed, Highly Virulent, and Nosocomial.
Baylor University Medical Center Proceedings,
Vol. 19,
Issue. 1,
p.
3.
Dhalla, Irfan A.
Mamdani, Muhammad M.
Simor, Andrew E.
Kopp, Alex
Rochon, Paula A.
and
Juurlink, David N.
2006.
Are Broad-Spectrum Fluoroquinolones More Likely To Cause
Clostridium difficile
-Associated Disease?
.
Antimicrobial Agents and Chemotherapy,
Vol. 50,
Issue. 9,
p.
3216.
Babcock, Gregory J.
Broering, Teresa J.
Hernandez, Hector J.
Mandell, Robert B.
Donahue, Katherine
Boatright, Naomi
Stack, Anne M.
Lowy, Israel
Graziano, Robert
Molrine, Deborah
Ambrosino, Donna M.
and
Thomas, William D.
2006.
Human Monoclonal Antibodies Directed against Toxins A and B Prevent
Clostridium difficile
-Induced Mortality in Hamsters
.
Infection and Immunity,
Vol. 74,
Issue. 11,
p.
6339.
Novak, Joshua
and
Katz, Jeffry A.
2006.
Probiotics and prebiotics for gastrointestinal infections.
Current Infectious Disease Reports,
Vol. 8,
Issue. 2,
p.
103.
Thorpe, Cheleste M.
and
Gorbach, Sherwood L.
2006.
Update on Clostridium difficile
.
Current Treatment Options in Gastroenterology,
Vol. 9,
Issue. 3,
p.
265.
Pepin, Jacques
2006.
Editorial Commentary:Improving the Treatment ofClostridium difficile–Associated Disease: Where Should We Start?.
Clinical Infectious Diseases,
Vol. 43,
Issue. 5,
p.
553.
Boyce, John M.
Ligi, Cathy
Kohan, Cindy
Dumigan, Diane
and
Havill, Nancy L.
2006.
Lack of Association Between the Increased Incidence ofClostridium difficile–Associated Disease and the Increasing Use of Alcohol-Based Hand Rubs.
Infection Control & Hospital Epidemiology,
Vol. 27,
Issue. 5,
p.
479.
Valiquette, L.
Low, D. E.
Chow, R.
and
McGeer, A. J.
2006.
A survey of physician's attitudes regarding management of severe group A streptococcal infections.
Scandinavian Journal of Infectious Diseases,
Vol. 38,
Issue. 11-12,
p.
977.
Cappelletty, Diane M
and
Zervos, Mark
2006.
Levofloxacin Use in the Elderly: Focus on Pneumonia.
Aging Health,
Vol. 2,
Issue. 3,
p.
371.
YEARSLEY, K. A.
GILBY, L. J.
RAMADAS, A. V.
KUBIAK, E. M.
FONE, D. L.
and
ALLISON, M. C.
2006.
Proton pump inhibitor therapy is a risk factor for Clostridium difficile‐associated diarrhoea.
Alimentary Pharmacology & Therapeutics,
Vol. 24,
Issue. 4,
p.
613.
Surowiec, Dorothy
Kuyumjian, Arpi G
Wynd, Michael A
and
Cicogna, Cristina E
2006.
Past, Present, and Future Therapies for Clostridium difficile–Associated Disease.
Annals of Pharmacotherapy,
Vol. 40,
Issue. 12,
p.
2155.
Aslam, Saima
and
Musher, Daniel M.
2006.
An Update on Diagnosis, Treatment, and Prevention of Clostridium difficile–Associated Disease.
Gastroenterology Clinics of North America,
Vol. 35,
Issue. 2,
p.
315.
Bhalla, Alka
2006.
Quinolones: A Nosocomial Risk Factor for Clostridium Difficile—Associated Diarrhea.
Canadian Pharmacists Journal / Revue des Pharmaciens du Canada,
Vol. 139,
Issue. 2,
p.
47.